Safe Prescribing — MCQs

A 56-year-old man with type 2 diabetes is admitted with pneumonia. His regular medications include metformin 1g twice daily and gliclazide 80mg twice daily. On admission, his blood glucose is 18.2 mmol/L, serum creatinine 156 μmol/L (baseline 95 μmol/L), lactate 3.2 mmol/L, and he is haemodynamically stable. What is the most appropriate management of his diabetic medications?

Q224

A 45-year-old woman is prescribed azathioprine for Crohn's disease. Before starting treatment, thiopurine methyltransferase (TPMT) enzyme activity testing shows she has intermediate TPMT activity. What is the most appropriate prescribing action?

Q225

A 74-year-old man with heart failure is taking spironolactone 25mg daily. His recent blood tests show potassium 5.8 mmol/L (normal range 3.5-5.0 mmol/L) and eGFR 42 ml/min/1.73m². Which medication from his regular list is most likely to be contributing to the hyperkalaemia alongside spironolactone?

Q226

A 62-year-old woman with hypertension and chronic kidney disease (eGFR 35 ml/min/1.73m²) is prescribed an angiotensin-converting enzyme (ACE) inhibitor. According to national prescribing guidelines, what is the most appropriate timeframe for checking her renal function after initiating therapy?

Q227

A 68-year-old man with venous thromboembolism is established on apixaban. He develops acute kidney injury with his eGFR dropping from 65ml/min/1.73m² to 22ml/min/1.73m² secondary to sepsis. His weight is 80kg. What is the most appropriate modification to his anticoagulation?

Q228

A 38-year-old woman with newly diagnosed type 1 diabetes is being initiated on insulin therapy. She weighs 70kg. Following best practice guidelines for initial insulin dosing in type 1 diabetes, what would be the most appropriate total daily insulin dose to start?

Q229

A 55-year-old man with rheumatoid arthritis has been on methotrexate 20mg weekly for 3 years with good disease control. He attends for routine monitoring bloods. Results show: Hb 142g/L, WCC 3.2×10⁹/L, neutrophils 1.6×10⁹/L, platelets 178×10⁹/L, ALT 68 U/L (normal 10-40), AST 58 U/L (normal 10-40), ALP 82 U/L (normal 30-130), bilirubin 14 μmol/L (normal 3-17). He is asymptomatic. What is the most appropriate management?

Q230

A 70-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He undergoes emergency surgery for a ruptured appendix. His last dose of rivaroxaban was 8 hours ago. He is bleeding significantly during surgery. What is the most appropriate management for rivaroxaban reversal?

Safe Prescribing UK Medical PG Practice Questions and MCQs

Question 221: A 29-year-old woman with type 1 diabetes is found unconscious at home by her partner. Paramedics measure her blood glucose at 1.8 mmol/L. She has no intravenous access available. What is the most appropriate immediate treatment?

A. Administer 1mg intramuscular glucagon (Correct Answer)
B. Administer 15g oral glucose gel into buccal cavity
C. Administer 75ml of 20% glucose via intraosseous route
D. Establish intravenous access and give 100ml 10% glucose
E. Administer 10 units intramuscular rapid-acting insulin

Explanation: ***Administer 1mg intramuscular glucagon*** - In an **unconscious patient** with severe hypoglycaemia (1.8 mmol/L) and **no intravenous access**, IM glucagon is the first-line treatment to stimulate **hepatic glycogenolysis**. - It is effective, can be administered quickly by paramedics, and typically raises blood glucose levels within **10-15 minutes**. *Administer 15g oral glucose gel into buccal cavity* - Oral treatments, including glucose gels, are strictly **contraindicated** in unconscious patients due to the high risk of **aspiration**. - Absorption through the buccal mucosa is **unreliable and slow** compared to parenteral routes in an emergency setting. *Administer 75ml of 20% glucose via intraosseous route* - The **intraosseous (IO) route** is technically demanding and requires specialist equipment, making it a secondary option when **IM glucagon** can be given more easily. - IO access is generally reserved for **resuscitation** scenarios after both IV and IM options have been considered or failed. *Establish intravenous access and give 100ml 10% glucose* - While **IV glucose** is the preferred treatment for severe hypoglycaemia, attempting to establish access in a collapsed patient can cause **dangerous delays**. - The priority is to provide immediate glucose-raising therapy via the **intramuscular route** since the patient currently lacks access. *Administer 10 units intramuscular rapid-acting insulin* - Insulin lowers blood glucose; administering it to a patient with a level of 1.8 mmol/L would be **fatal**. - This intervention would worsen the **neuroglycopenia** and potentially lead to irreversible brain damage or death.

Question 222: A 71-year-old woman with atrial fibrillation on warfarin (target INR 2-3) presents with epistaxis. Her INR is 7.2. She has no other bleeding and is haemodynamically stable. According to current guidelines, what is the most appropriate immediate management?

A. Give 5mg intravenous vitamin K and 4-factor prothrombin complex concentrate
B. Give 5mg oral vitamin K and withhold warfarin until INR in target range
C. Withhold 1-2 doses of warfarin and recheck INR daily
D. Give 1-2mg intravenous vitamin K and withhold warfarin (Correct Answer)
E. Give fresh frozen plasma and withhold warfarin

Explanation: ***Give 1-2mg intravenous vitamin K and withhold warfarin***- For a patient with an **elevated INR (5.0-9.0)** and **minor bleeding** like epistaxis, guidelines recommend **1-2mg intravenous Vitamin K** to achieve rapid partial reversal. - This dose helps reduce the bleeding risk without causing **prolonged warfarin resistance**, facilitating easier re-warfarinisation when appropriate. Warfarin must also be withheld.*Give 5mg intravenous vitamin K and 4-factor prothrombin complex concentrate*- **Prothrombin complex concentrate (PCC)** and high-dose Vitamin K are reserved for **major or life-threatening bleeding** (e.g., intracranial hemorrhage, hemodynamic instability). - Administering PCC in a hemodynamically stable patient with minor epistaxis carries an unnecessary risk of **thromboembolic events**.*Give 5mg oral vitamin K and withhold warfarin until INR in target range*- While **oral Vitamin K** is suitable for high INR without bleeding, the **intravenous route** is preferred for active bleeding due to its faster onset of action. - A **5mg dose** of Vitamin K is often higher than needed for minor bleeding and may lead to **prolonged warfarin resistance**, complicating future anticoagulation.*Withhold 1-2 doses of warfarin and recheck INR daily*- This strategy is appropriate for patients with an **INR between 4.5 and 8.0** who have **no bleeding**. - Since the patient is actively bleeding (epistaxis), merely withholding warfarin is insufficient; active reversal with **Vitamin K** is indicated to promptly reduce the bleeding risk.*Give fresh frozen plasma and withhold warfarin*- **Fresh frozen plasma (FFP)** is less effective than **PCC** for rapid warfarin reversal, requiring larger volumes and posing risks of **volume overload**. - FFP is generally considered only if PCC is unavailable or contraindicated, and primarily for **major, life-threatening hemorrhage**, not minor epistaxis in a stable patient.

Question 223: A 56-year-old man with type 2 diabetes is admitted with pneumonia. His regular medications include metformin 1g twice daily and gliclazide 80mg twice daily. On admission, his blood glucose is 18.2 mmol/L, serum creatinine 156 μmol/L (baseline 95 μmol/L), lactate 3.2 mmol/L, and he is haemodynamically stable. What is the most appropriate management of his diabetic medications?

A. Continue both metformin and gliclazide at current doses
B. Stop metformin, continue gliclazide, and start variable rate intravenous insulin infusion
C. Stop metformin and gliclazide, start fixed dose subcutaneous insulin
D. Continue gliclazide, stop metformin temporarily, and add basal-bolus insulin regime (Correct Answer)
E. Reduce metformin dose by 50%, continue gliclazide, and monitor closely

Explanation: ***Continue gliclazide, stop metformin temporarily, and add basal-bolus insulin regime*** - **Metformin** must be withheld due to the presence of **acute kidney injury (AKI)** evidenced by a rising creatinine (156 μmol/L) and a raised **lactate** (3.2 mmol/L), which increases the risk of **lactic acidosis**. - A **basal-bolus insulin** regimen is the preferred method for managing **hyperglycemia** (18.2 mmol/L) in a non-critically ill, hemodynamically stable patient who is eating and drinking during an acute infection. *Continue both metformin and gliclazide at current doses* - Continuing metformin in the setting of **AKI** and **sepsis** is contraindicated because it can lead to toxic accumulation and **metformin-associated lactic acidosis (MALA)**. - This approach ignores the significant hyperglycemia, which requires more intensive titration than oral agents can provide during acute illness. *Stop metformin, continue gliclazide, and start variable rate intravenous insulin infusion* - **Variable rate intravenous insulin infusion (VRIII)** is usually reserved for patients who are **NBM (nil by mouth)**, hemodynamically unstable, or in **DKA/HHS**. - Since the patient is stable and likely consuming meals, **subcutaneous insulin** is safer and more appropriate for glycemic control. *Stop metformin and gliclazide, start fixed dose subcutaneous insulin* - While stopping metformin is correct, discontinuing all oral agents can lead to poor control if the **fixed-dose insulin** is not carefully calculated to cover basal and nutritional needs. - **Basal-bolus** regimens are superior to simple fixed-dose regimens as they offer better flexibility for glucose monitoring and meal-related adjustments. *Reduce metformin dose by 50%, continue gliclazide, and monitor closely* - Dose reduction is inappropriate in the context of an **acute rise** in creatinine and **elevated lactate**; complete temporary cessation is the standard safety protocol. - Simple monitoring without adding **insulin therapy** will not sufficiently address the severe hyperglycemia (18.2 mmol/L) caused by the **stress response** to pneumonia.

Question 224: A 45-year-old woman is prescribed azathioprine for Crohn's disease. Before starting treatment, thiopurine methyltransferase (TPMT) enzyme activity testing shows she has intermediate TPMT activity. What is the most appropriate prescribing action?

A. Start standard dose azathioprine with weekly full blood count monitoring
B. Start azathioprine at 50% of standard dose with increased monitoring (Correct Answer)
C. Avoid azathioprine completely and select an alternative agent
D. Start standard dose azathioprine with monthly full blood count monitoring
E. Start azathioprine at 75% of standard dose with standard monitoring

Explanation: ***Start azathioprine at 50% of standard dose with increased monitoring*** - Patients with **intermediate TPMT activity** (heterozygous) have a reduced capacity to metabolize azathioprine, leading to higher levels of active 6-TGN metabolites and increased risk of **myelosuppression**. - A **50% dose reduction** combined with frequent **full blood count (FBC)** monitoring allows for safe treatment while mitigating the risk of toxic side effects. *Start standard dose azathioprine with weekly full blood count monitoring* - Initiating a **standard dose** in a patient with reduced TPMT activity significantly increases the danger of rapid and severe **bone marrow suppression**. - Monitoring alone is insufficient to prevent toxicity if the initial dose exceeds the patient's metabolic capacity to clear the drug. *Avoid azathioprine completely and select an alternative agent* - **Complete avoidance** is typically reserved for patients with **absent TPMT activity** (homozygous deficiency), which occurs in roughly 0.3% of the population. - Patients with intermediate activity can still derive clinical benefit from **thiopurines** provided the dosage is carefully titrated downwards. *Start standard dose azathioprine with monthly full blood count monitoring* - **Monthly monitoring** is inadequate even for patients with normal TPMT activity during the initiation phase; it is dangerously infrequent for those at high risk. - A **standard dose** is contraindicated here as it would likely lead to toxic accumulations of active metabolites. *Start azathioprine at 75% of standard dose with standard monitoring* - A **75% dose** is often still too high for intermediate metabolizers and does not align with the safety margin provided by a **50% reduction**. - **Standard monitoring** is insufficient; these patients require **increased surveillance** to detect early signs of leucopenia or thrombocytopenia.

Question 225: A 74-year-old man with heart failure is taking spironolactone 25mg daily. His recent blood tests show potassium 5.8 mmol/L (normal range 3.5-5.0 mmol/L) and eGFR 42 ml/min/1.73m². Which medication from his regular list is most likely to be contributing to the hyperkalaemia alongside spironolactone?

A. Furosemide 40mg twice daily
B. Bisoprolol 5mg once daily
C. Ramipril 5mg once daily (Correct Answer)
D. Digoxin 125mcg once daily
E. Atorvastatin 40mg once daily

Explanation: ***Ramipril 5mg once daily*** - **ACE inhibitors** like ramipril block the conversion of angiotensin I to angiotensin II, leading to decreased **aldosterone** secretion and reduced renal **potassium excretion**. - Using an ACE inhibitor concurrently with **spironolactone** (a potassium-sparing diuretic) significantly increases the risk of **hyperkalaemia**, especially in patients with **renal impairment** (eGFR < 60 ml/min/1.73m²). *Furosemide 40mg twice daily* - Furosemide is a **loop diuretic** that typically promotes the excretion of potassium in the urine, leading to **hypokalaemia** rather than hyperkalaemia. - It is often used to counteract the potassium-retaining effects of drugs like spironolactone, making it an unlikely cause of elevated potassium. *Bisoprolol 5mg once daily* - Bisoprolol is a **beta-blocker** used in heart failure management that generally has a **minimal effect** on serum potassium levels at therapeutic doses. - While beta-blockers can theoretically interfere with potassium shift into cells, they are not a primary driver of clinically significant **hyperkalaemia** compared to mineralocorticoid antagonists. *Digoxin 125mcg once daily* - Digoxin inhibits the **Na+/K+-ATPase pump**, but significant hyperkalaemia is usually only seen in cases of **acute toxicity** or severe overdose. - In therapeutic doses, it does not typically contribute to the chronic elevation of potassium levels observed in this patient. *Atorvastatin 40mg once daily* - Atorvastatin is an **HMG-CoA reductase inhibitor** used for lipid lowering and has **no direct mechanism** or clinical association with serum potassium elevation. - Its primary monitoring requirements involve **liver enzymes** and **creatine kinase**, not electrolyte balances.

Question 226: A 62-year-old woman with hypertension and chronic kidney disease (eGFR 35 ml/min/1.73m²) is prescribed an angiotensin-converting enzyme (ACE) inhibitor. According to national prescribing guidelines, what is the most appropriate timeframe for checking her renal function after initiating therapy?

A. After 3 months of starting treatment
B. Within 24 hours of starting treatment
C. After 1-2 weeks of starting treatment (Correct Answer)
D. After 4 weeks of starting treatment
E. Only if symptoms of renal impairment develop

Explanation: ***After 1-2 weeks of starting treatment***- National guidelines recommend monitoring **renal function (U&Es)** and **potassium levels** within 1 to 2 weeks of initiating an **ACE inhibitor** or increasing the dose.- This timeframe is critical for identifying potential **acute kidney injury** or significant **hyperkalemia**, especially in high-risk patients with pre-existing **Chronic Kidney Disease (CKD)**.*Within 24 hours of starting treatment*- Monitoring within 24 hours is unnecessarily frequent and usually too early to see the full physiologic impact of **efferent arteriolar vasodilation** on serum creatinine.- This level of urgency is typically reserved for patients with **acute clinical instability** rather than routine outpatient management of hypertension or CKD.*After 4 weeks of starting treatment*- Waiting 4 weeks is considered too long for a patient with an **eGFR of 35 ml/min**, as significant renal deterioration could occur undetected.- Early detection is required to manage a rise in **creatinine** (acceptable up to 30%) or a dangerous rise in **potassium** early in the course of therapy.*After 3 months of starting treatment*- This timeframe is appropriate for **routine maintenance monitoring** once a patient is on a stable, long-term dose of an ACE inhibitor.- It is unsafe for the initial **titration phase**, where the risk of **renal dysfunction** and electrolyte imbalance is at its highest.*Only if symptoms of renal impairment develop*- **Renal impairment** and **hyperkalemia** are often asymptomatic until they become severe or life-threatening.- Relying on symptoms rather than **biochemical monitoring** is dangerous and contradicts standard safety protocols for drugs affecting the **Renin-Angiotensin-Aldosterone System (RAAS)**.

Question 227: A 68-year-old man with venous thromboembolism is established on apixaban. He develops acute kidney injury with his eGFR dropping from 65ml/min/1.73m² to 22ml/min/1.73m² secondary to sepsis. His weight is 80kg. What is the most appropriate modification to his anticoagulation?

A. Continue apixaban at current dose as it is minimally renally excreted
B. Reduce apixaban dose from 5mg twice daily to 2.5mg twice daily
C. Switch to warfarin with target INR 2-3 (Correct Answer)
D. Stop apixaban and give prophylactic dose LMWH
E. Stop apixaban and start intravenous unfractionated heparin infusion

Explanation: ***Switch to warfarin with target INR 2-3*** - Apixaban is **contraindicated** or should be used with extreme caution when the **creatinine clearance** falls below 15-30 ml/min due to the risk of drug accumulation and major hemorrhage. - **Warfarin** is the preferred long-term anticoagulant in severe renal impairment (CKD stage 4/5) because it is metabolized by the **liver** and its effect is easily monitored via **INR**. *Continue apixaban at current dose as it is minimally renally excreted* - Approximately **27% of apixaban** is renally excreted, making it the least renally cleared DOAC, but still unsafe at an **eGFR of 22 ml/min**. - Continuing the full dose during **acute kidney injury** significantly increases the patient's risk of life-threatening bleeding. *Reduce apixaban dose from 5mg twice daily to 2.5mg twice daily* - Dose reduction criteria for apixaban (age ">=80, weight ">=60kg, or creatinine ">=133 mol/L) applies primarily to **atrial fibrillation**, not necessarily therapeutic VTE treatment in acute failure. - Even at a reduced dose, the safety profile of apixaban is not well-established for patients with an **eGFR <30 ml/min** in the context of active VTE treatment. *Stop apixaban and give prophylactic dose LMWH* - **Low Molecular Weight Heparin (LMWH)** is renally excreted and will accumulate in a patient with an **eGFR of 22 ml/min**, increasing bleeding risk. - A **prophylactic dose** is insufficient for a patient who has established **venous thromboembolism (VTE)** and requires therapeutic-grade anticoagulation. *Stop apixaban and start intravenous unfractionated heparin infusion* - While **Unfractionated Heparin (UFH)** is safe in renal failure, it requires **continuous intravenous access** and intensive APTT monitoring, making it impractical for stable long-term management outside of an acute hospital setting. - UFH is typically reserved for the **initial stabilization** of unstable VTE or perioperative bridging, rather than a long-term alternative for stable outpatients.

Question 228: A 38-year-old woman with newly diagnosed type 1 diabetes is being initiated on insulin therapy. She weighs 70kg. Following best practice guidelines for initial insulin dosing in type 1 diabetes, what would be the most appropriate total daily insulin dose to start?

A. 20 units (0.3 units/kg/day) split as 50% basal and 50% bolus
B. 35 units (0.5 units/kg/day) split as 50% basal and 50% bolus (Correct Answer)
C. 70 units (1.0 units/kg/day) split as 40% basal and 60% bolus
D. 14 units (0.2 units/kg/day) as basal insulin only
E. 105 units (1.5 units/kg/day) split as 50% basal and 50% bolus

Explanation: ***35 units (0.5 units/kg/day) split as 50% basal and 50% bolus*** - For a newly diagnosed adult with **Type 1 Diabetes**, the standard initial **Total Daily Dose (TDD)** is typically **0.4 to 0.6 units/kg/day**. For a 70kg patient, 0.5 units/kg/day equals 35 units. - This dose is ideally split into **50% basal insulin** to suppress hepatic glucose production between meals and **50% bolus (prandial) insulin** to cover carbohydrate intake. *20 units (0.3 units/kg/day) split as 50% basal and 50% bolus* - An initial dose of **0.3 units/kg/day** is often considered too low for an adult with T1DM and may result in persistent **hyperglycemia** during the initiation phase. - While safer for patients with high insulin sensitivity or those in a **'honeymoon phase'**, it is not the standard starting recommendation for a typical 70kg adult. *70 units (1.0 units/kg/day) split as 40% basal and 60% bolus* - Starting at **1.0 units/kg/day** is excessively high for a fresh diagnosis and carries a significant risk of severe **iatrogenic hypoglycemia**. - Such high doses are generally reserved for patients with significant **insulin resistance**, such as those with obesity or during acute **illness/sepsis**. *14 units (0.2 units/kg/day) as basal insulin only* - **Basal-only regimens** are inappropriate for Type 1 Diabetes because these patients have an **absolute insulin deficiency** and require prandial coverage to manage post-meal glucose spikes. - Using only basal insulin at such a low dose would likely lead to inadequate glycemic control and a potential risk of **diabetic ketoacidosis (DKA)**. *105 units (1.5 units/kg/day) split as 50% basal and 50% bolus* - A dose of **1.5 units/kg/day** is extremely aggressive and dangerous for an initial prescription in a non-obese patient. - This level of dosing is far beyond the physiological requirement for a newly diagnosed patient and would almost certainly cause **hypoglycemic emergencies**.

Question 229: A 55-year-old man with rheumatoid arthritis has been on methotrexate 20mg weekly for 3 years with good disease control. He attends for routine monitoring bloods. Results show: Hb 142g/L, WCC 3.2×10⁹/L, neutrophils 1.6×10⁹/L, platelets 178×10⁹/L, ALT 68 U/L (normal 10-40), AST 58 U/L (normal 10-40), ALP 82 U/L (normal 30-130), bilirubin 14 μmol/L (normal 3-17). He is asymptomatic. What is the most appropriate management?

A. Stop methotrexate permanently due to hepatotoxicity
B. Continue methotrexate and recheck liver function in 2 weeks
C. Reduce methotrexate dose to 15mg weekly and recheck bloods in 1 week
D. Temporarily withhold methotrexate and recheck liver function in 1-2 weeks; consider restarting at reduced dose if improving (Correct Answer)
E. Continue methotrexate but add ursodeoxycholic acid for hepatoprotection

Explanation: ***Temporarily withhold methotrexate and recheck liver function in 1-2 weeks; consider restarting at reduced dose if improving*** - The patient's **ALT** and **AST** are elevated (ALT 1.7x ULN, AST 1.45x ULN), along with mild **neutropenia**, indicating **methotrexate toxicity**. - Temporarily withholding the drug allows the liver and bone marrow to recover, and subsequent **dose reduction** upon improvement helps prevent recurrence while maintaining disease control. *Stop methotrexate permanently due to hepatotoxicity* - Permanent discontinuation is typically reserved for more severe adverse effects, such as persistent **ALT/AST** elevation >3 times the **ULN** despite temporary withdrawal, or signs of significant **liver damage** like fibrosis. - In this case, the **transaminase** elevation is moderate, and the patient is asymptomatic, suggesting that the toxicity is likely reversible with appropriate management. *Continue methotrexate and recheck liver function in 2 weeks* - Continuing **methotrexate** at the current dose with elevated **liver enzymes** and **neutropenia** risks exacerbating **hepatotoxicity** and **myelosuppression**. - Monitoring guidelines mandate intervention, such as dose adjustment or temporary cessation, when **transaminase levels** exceed 1.5-2 times the **ULN**. *Reduce methotrexate dose to 15mg weekly and recheck bloods in 1 week* - While **dose reduction** might be part of the long-term management, the initial step for elevated **liver enzymes** and **myelosuppression** is usually a temporary cessation to allow for recovery. - A direct dose reduction without a brief drug holiday may not be sufficient to adequately reverse the observed **toxicity** and ensure patient safety. *Continue methotrexate but add ursodeoxycholic acid for hepatoprotection* - **Ursodeoxycholic acid** is primarily used to dissolve gallstones or treat **cholestatic liver diseases** like **Primary Biliary Cholangitis** by altering bile acid composition. - It has no established role or evidence in preventing or treating **methotrexate-induced hepatotoxicity**, which is a direct cytotoxic effect on hepatocytes.

Question 230: A 70-year-old man with atrial fibrillation is on rivaroxaban 20mg once daily. He undergoes emergency surgery for a ruptured appendix. His last dose of rivaroxaban was 8 hours ago. He is bleeding significantly during surgery. What is the most appropriate management for rivaroxaban reversal?

A. Administer vitamin K 10mg intravenously
B. Administer prothrombin complex concentrate (PCC) 50 units/kg
C. Administer andexanet alfa if available, or PCC if not (Correct Answer)
D. Administer fresh frozen plasma 15-20ml/kg
E. Administer tranexamic acid 1g intravenously

Explanation: ***Administer andexanet alfa if available, or PCC if not*** - **Andexanet alfa** is the specific, licensed reversal agent for **Factor Xa inhibitors** like rivaroxaban; it acts as a **decoy receptor** to neutralize the drug's effect. - In life-threatening or uncontrolled bleeding where the last dose was recent (~8 hours), **prothrombin complex concentrate (PCC)** is the secondary recommendation if andexanet is unavailable. *Administer vitamin K 10mg intravenously* - **Vitamin K** is only effective for reversing **Vitamin K Antagonists** (e.g., Warfarin) by assisting the synthesis of factors II, VII, IX, and X. - It has no role in reversing **Direct Oral Anticoagulants (DOACs)** like rivaroxaban, which inhibit clotting factors directly. *Administer prothrombin complex concentrate (PCC) 50 units/kg* - While 4-factor **PCC** is used when specific agents are unavailable, it is not the primary choice if **andexanet alfa** is on hand. - PCC works by providing a high concentration of **clotting factors** to overwhelm the inhibitor, but it does not directly neutralize the rivaroxaban molecule. *Administer fresh frozen plasma 15-20ml/kg* - **Fresh Frozen Plasma (FFP)** is generally ineffective for DOAC reversal because it requires **excessive volumes** to achieve the necessary concentration of factors. - Using FFP carries a significant risk of **transfusion-associated circulatory overload (TACO)** and is not recommended over PCC or specific antidotes. *Administer tranexamic acid 1g intravenously* - **Tranexamic acid** is an **antifibrinolytic** that prevents the breakdown of clots; it is a supportive measure rather than a direct reversal agent. - While often used in major trauma or surgical bleeding, it cannot reverse the **Factor Xa inhibition** caused by rivaroxaban.

Practice by Chapter

Anticoagulant safety

Practice Questions

High-risk medicines

Practice Questions

Insulin safety

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free